Golimumab (Simponi®)

Assessment Status Assessment process complete
Drug Golimumab
Brand (Simponi®)
Indication For the treatment of moderate to severe rheumatoid arthritis.
Assessment Process
Rapid review commissioned 20/11/2009
Rapid review completed 11/05/2010
Rapid review outcome Reimbursement recommended following price review, June 2010.

The review group did not consider golimumab cost-effective at the submitted price in May 2010.

Following a price reduction the review group now consider golimumab to be cost-effective. June 2010.

Technical Summary